ZyVersa Therapeutics Stock (NASDAQ: ZVSA)

Dernières nouvelles pour ZyVersa Therapeutics (NASDAQ:ZVSA) Stock

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

Jack Henry &amp; Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.61 by 1.24 percent. This is a 17.27 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $600.98 million which beat the analyst consensus estimate of $600.11 million by 0.15 percent. This is a 5.18 percent increase over sales of $571.37 million the same period last year.

Earnings

Earnings Beats

News

JKHY

Jack Henry & Associates Q1 EPS $1.63 Beats $1.61 Estimate, Sales $600.98M Beat $600.11M Estimate

B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.20 by 35 percent. The company reported quarterly sales of $461.10 million which missed the analyst consensus estimate of $473.12 million by 2.54 percent. This is a 8.28 percent decrease over sales of $502.73 million the same period last year.

Earnings Misses

B&G Foods Q3 2024 Adj EPS $0.13 Misses $0.20 Estimate, Sales $461.10M Miss $473.12M Estimate

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

Guidance

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.03) by 2800 percent. This is a 245 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $88.43 million which missed the analyst consensus estimate of $94.21 million by 6.14 percent. This is a 1.75 percent increase over sales of $86.91 million the same period last year.

AVNW

Aviat Networks Q1 Adj $(0.87) Misses $(0.03) Estimate, Sales $88.43M Miss $94.21M Estimate

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) lowers FY2024 sales outlook from $231.00 million-235.00 million to $230.00 million-232.00 million.

VTEX

Vtex Lowers FY2024 Sales Guidance from $231.00M-235.00M to $230.00M-232.00M.

MASI

Masimo Sees Q4 Revenue $581M-$611M; Q4 Adj. EPS $1.35-$1.50

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees Q4 sales of $64.800 million-66.800 million vs $67.57 million estimate.

Vtex Sees Q4 Sales $64.800M-66.800M vs $67.57M Est.

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.02) by 3.92 percent. The company reported quarterly sales of $12.500 million which beat the analyst consensus estimate of $11.199 million by 11.62 percent.

SNDX

Syndax Pharmaceuticals Q3 2024 GAAP EPS $(0.98) Beats $(1.02) Estimate, Sales $12.500M Beat $11.199M Estimate

Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. The company reported quarterly sales of $45.086 million which beat the analyst consensus estimate of $43.484 million by 3.68 percent. This is a 10.62 percent increase over sales of $40.758 million the same period last year.

TMCI

Treace Medical Concepts Q3 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate, Sales $45.086M Beat $43.484M Estimate

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.14 by 14.04 percent.

Devon Energy Q3 2024 GAAP EPS $1.30 Beats $1.14 Estimate

Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.01 by 500 percent. The company reported quarterly sales of $7.90 billion which beat the analyst consensus estimate of $7.76 billion by 1.79 percent. This is a 27.75 percent increase over sales of $6.18 billion the same period last year.

CPNG

Coupang Q3 2024 Adj EPS $0.06 Beats $0.01 Estimate, Sales $7.90B Beat $7.76B Estimate

Ever wondered <a href="https://www.benzinga.com/personal-finance/24/10/41193824/are-you-rich-enough-to-be-in-the-top-1-heres-both-the-income-and-net-worth-you-need-to-rank-amon">how your finances measure up?</a> You're not alone. We often think about where we stand compared to others financially – though few of us like to admit it. Getting a sense of your financial health can be motivating, especially when it's not about competition but about setting realistic goals for yourself.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved? <a href="https://www.benzinga.com/money/red-ventures" target="_blank" rel="noreferrer noopener">The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>
What is Net Worth, Really?
Before diving into numbers, clarifying what "net worth" means is important. Simply put, it's what you own (assets) minus what you owe (liabilities). Assets include things like your home, car, investments and savings. Liabilities are things like mortgages, credit card debt and student loans. Think of net worth as a quick snapshot of your financial health. It's a bigger picture than income alone, revealing how much you've kept.
See Also: Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a>
Net Worth by Income Level
According to the Federal Reserve's latest data, here's how net worth varies across different income brackets:
<ul>
<li>Under $34,600: Median net worth of $14,000, average of $129,700</li>
<li>$34,600-$59,499: Median of $71,000, average of $218,700</li>
<li>$59,500-$91,899: Median of $159,300, average of $385,400</li>
<li>$91,900-$153,099: Median of $307,200, average of $636,800</li>
<li>$153,100-$245,399: Median of $747,000, average of $1,264,700</li>
<li>$245,400 and higher: Median of $2,556,200, average of $6,629,600</li>
</ul>
Upper-income households in the U.S. generally have a net worth significantly higher than lower-income households. According to Pew Research Center, the median net worth of upper-income households is roughly 7.3 times greater than that of middle-income households, and 75 times that of lower-income households.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
What You Can Learn from the Data
There are a few standout takeaways:
Median vs. Average: The U.S. household median net worth is $192,700, while the average is around $1.06 million. The gap highlights how high-net-worth individuals skew the overall average.
Age Matters: Net worth tends to peak for those aged 65-74, averaging around $1.78 million. Years of saving and investing build up.
Education's Impact: A college degree matters here – graduates have over 11 times the net worth of people without a high school diploma.
Location, Location, Location: Urban dwellers typically have higher net worthy than those in rural areas, largely due to property values.
Wealth Gap: Unfortunately, the racial wealth gap remains stark, with white households holding considerably higher net worthy on average than Black and Latino households.
Trending: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually, <a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor" target="_blank" rel="noreferrer noopener">here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
Steps to Boost Your Net Worth
Regardless of where you currently fall, there are practical ways to improve your financial standing:
<ul>
<li>Pay Off High-Interest Debt: Start with credit card balances and other high-interest debts, which can drain your finances fast.</li>
</ul>
<ul>
<li>Save and Invest: Aim to set aside at least 20% of your income and automate it if you can. Investing early helps, too.</li>
</ul>
<ul>
<li>Leverage Retirement Accounts: Contribute to 401(k)s or IRAs, especially if your employer matches contributions.</li>
</ul>
<ul>
<li>Diversify: Spread your investments across stocks, bonds and real estate to manage risk and grow wealth.</li>
</ul>
<ul>
<li>Find Extra Income Streams: Side hustles, freelance work or passive income can boost your finances.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
<ul>
<li>Keep Learning: Educate yourself about personal finance and stay updated on tax strategies and investment options.</li>
</ul>
<ul>
<li>Live Below Your Means: Resist lifestyle inflation even as your income grows. Focus on assets, not material things.</li>
</ul>
<ul>
<li>Invest in Yourself: Whether it's more education or a new skill, growing your potential can lead to better income.</li>
</ul>
<ul>
<li>Check In on Your Goals: Adjust your financial plan as your life and income evolve.</li>
</ul>
<ul>
<li>Seek Professional Guidance: A <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">financial advisor can help you</a> strategize if it feels overwhelming.</li>
</ul>
Comparing your finances to others can motivate you, but remember that everyone's journey is different. Focus on realistic, personal goals that fit your life. Building wealth takes time – it's a marathon, not a sprint. With steady, smart choices, you'll see growth in your net worth over time. Regardless of where you stand now, there's always room to move toward a more secure financial future.
This story was updated to reflect updated research numbers for upper household income net worth vs. lower-income households.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211; <a href="https://www.benzinga.com/money/retire-5mil-nest-egg" target="_blank" rel="noreferrer noopener">How does it compare to the average?</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Personal Finance

Are You Richer Or Poorer Than Your Peers? Here's A Look At The Average Net Worth For Your Income

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) narrows FY2024 sales outlook from $56.00 million-58.00 million to $56.90 million-57.90 million.

Arteris Narrows FY2024 Sales Guidance from $56.00M-58.00M to $56.90M-57.90M

Masimo Lowers FY24 Revenue From $2.085B-$2.135B To $2.075B-$2.105B Vs $2.100B Est; Raises FY24 Adj. EPS From $3.80-$4.00 To $3.95-$4.10 Vs $3.88 Est

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) sees Q4 sales of $14.700 million-15.700 million vs $14.92 million estimate.

Arteris Sees Q4 Sales $14.700M-15.700M vs $14.92M Est

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.52 by 19.23 percent. The company reported quarterly sales of $133.920 million which beat the analyst consensus estimate of $129.500 million by 3.41 percent. This is a 4.81 percent increase over sales of $127.768 million the same period last year.

Limbach Holdings Q3 2024 GAAP EPS $0.62 Beats $0.52 Estimate, Sales $133.920M Beat $129.500M Estimate

Tens of millions of people are expected to cast their ballots on Election Day Tuesday and the process has gone off relatively smoothly with some setbacks as voters decide a winner in the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
FBI Investigates Bomb Threats: Voters in some states were met with long lines in what <a href="https://www.benzinga.com/topic/election-poll">many election polls</a> show is a close matchup between Donald Trump and Kamala Harris.
Bomb threats at some polling locations delayed the voting process, with an investigation from the Federal Bureau of Investigation (FBI) linking the treats to Russia.
"The FBI is aware of bomb threats to polling locations in several states, many of which appear to originate from Russian email domains," the FBI said in a statement, as <a href="https://www.wsj.com/livecoverage/trump-harris-election-day-results-2024/card/russia-behind-bomb-threats-at-georgia-voting-sites-official-says-PB7RVxHIT33uLUk4IZK8">reported </a>by the Wall Street Journal. "None of the threats have been determined to be credible thus far."
The reported ties to Russia come as the United States has been on high alert for attempts by several countries to try and impact or influence the 2024 presidential election.
Russia has previously been accused of trying to influence the outcomes of the 2016 and 2020 presidential elections.
Read Also: <a href="https://www.benzinga.com/general/politics/24/10/41496316/microsoft-reports-russia-iran-china-stepping-up-efforts-to-influence-2024-election-voters-candid">Russia, Iran, China Step Up Efforts To Influence 2024 Election, Microsoft Says: Voters, Candidates &#8216;Must Remain Vigilant&#8217;</a>
Man Arrested at U.S. Capitol: A Michigan man was arrested by U.S. Capitol Police Tuesday at the Capitol Visitor Center.
The arrest came after the man, who smelled like fuel, was stopped during the screening process, as <a href="https://www.woodtv.com/news/nexstar-media-wire/us-capitol-police-arrest-michigan-man-with-torch-flare-gun-at-capitol-visitor-center/">reported </a>by WOODTV. The report said the man was found with a torch, flare gun and bottles with fuel residue inside.
"Our officers just arrested a man who was stopped during our screening process at the Capitol Visitor Center (CVC)," Capitol Police <a href="https://x.com/CapitolPolice/status/1853869248562475086">shared </a>on social media.
After the 28-year-old man from Jackson was arrested, the CVC closed for tours the rest of Tuesday.
Congress is not in session Tuesday, as <a href="https://thehill.com/regulation/court-battles/4973099-capitol-police-arrest-man-fuel-torch-flare-gun/">reported </a>by The Hill. Select members of the House will meet at 5 p.m. ET Tuesday for a brief pro forma session.
Voting Machine Problems: Voters in Cambria County, Pennsylvania will have an extra two hours to vote Tuesday due to a voting machine problem on Election Day, as <a href="https://www.wsj.com/livecoverage/trump-harris-election-day-results-2024?mod=lc_navigation">reported </a>by the Wall Street Journal.
After being a Democratic stronghold and voting for Barack Obama in the 2008 election, the county of 133,000 people is now a strong Republican-backed territory in the key swing state. Mitt Romney won the county in the 2012 election with 58% of the vote. Trump took 67% of the vote in the county in 2016 and 68% in 2020. 
High Alert, Minimal Problems: While the problems above have all occurred on Election Day, they come with the country on heightened alert and numerous problems expected.
The Washington Post <a href="https://www.washingtonpost.com/politics/2024/11/05/election-day-voting-millions-ballots-cast/">reported </a>that Election Day is "largely running smoothly" with only several small setbacks impacting locations Tuesday. <a href="https://www.wsj.com/livecoverage/trump-harris-election-day-results-2024/card/pennsylvania-county-awarded-extra-time-has-become-gop-stronghold-nZMZmSRRH4lDbxZq0vKp"></a>
One of the most common themes, which could be a sign of how important the 2024 election is and how close the results could be, is high voter turnout and long lines. Before polls opened Tuesday, <a href="https://www.benzinga.com/general/politics/24/11/41750069/80-million-votes-cast-in-early-voting-mail-in-voting-before-election-day-over-50-of-2020-electio">over 80 million votes </a>had already been cast by mail-in ballots or early in-person voting, equaling over half the total number of votes cast in the 2020 election.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41699037/fbi-uncovers-russian-backed-scheme-to-sway-2024-election-and-stoke-divisions-among-americans-with-fa">FBI Uncovers Russian-Backed Scheme To Sway 2024 Election And &#8216;Stoke Divisions Among Americans&#8217; With Fake Voter Fraud Video In Georgia</a></li>
</ul>
Photo generated using artificial intelligence via MidJourney.

Politics

Media

2024 Election Update: Bomb Threats From Russia, Man Arrested At US Capitol With Torch, Long Lines Top Issues Tuesday

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.08 by 4.63 percent. This is a 4.63 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $82.94 million which beat the analyst consensus estimate of $79.21 million by 4.72 percent. This is a 3.54 percent increase over sales of $80.11 million the same period last year.

National Health Investors Q3 FFO $1.03 Misses $1.08 Estimate, Sales $82.94M Beat $79.21M Estimate

Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 275 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $283.146 million which beat the analyst consensus estimate of $271.016 million by 4.48 percent. This is a 9.92 percent increase over sales of $257.603 million the same period last year.

RVLV

Revolve Gr Q3 2024 GAAP EPS $0.15 Beats $0.10 Estimate, Sales $283.146M Beat $271.016M Estimate

In connection with this workforce reduction, the Company expects to record restructuring charges of approximately $5.3 million primarily relating to severance packages and related benefits, with the majority of the restructuring charges anticipated in the fourth quarter of 2024.&nbsp;

IRBT

iRobot To Implement Operational Restructuring Plan That Is Expected To Include Overall Reduction Of Approximately 105 Employees, Representing 16% Of Global Workforce - Filing

ZyVersa Therapeutics GAAP EPS of -$3.31 beats by $0.44

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ZyVersa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/">ZVSA</a>) just reported results for the second quarter of 2024.<ul><li>ZyVersa Therapeutics reported earnings per share of -$3.31. This was above the analyst estimate for EPS of -$3.75.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/zvsa-stock-earnings-zyversa-therapeutics-for-q2-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024

ZyVersa Therapeutics files for mixed shelf offering

Warning: ZVSA is at high risk of performing badly

ZyVersa Therapeutics (ZVSA) highlights data from a review article published in the peer-reviewed journal, Life. The article summarizes data from 34...

ZyVersa highlights review article on inflammasome-induced inflammation

An announcement from ZyVersa Therapeutics ( ($ZVSA) ) is now available. ZyVersa Therapeutics' recent annual meeting saw key shareholder approvals, ...

ZyVersa Therapeutics' Shareholder Approvals and Director Elections

ZVSA

Screenshot 2024-03-29 at 1.05.42 AM

Biotech

General

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Health Care

Press Releases

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Analyst Ratings

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge"

ALBT

CRDL

PRSO

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apollomics

Bone Biologics

Bionomics Limited - American Depository Shares

Bionomics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Molecular Templates

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Scorpius Holdings

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

HC Wainwright & Co.

WIIM

ZyVersa Therapeutics shares are trading higher after the company highlighted data showing the potential of inflammasome inhibition to protect pancreatic islet beta cells and attenuate progression from obesity to insulin resistance and type 2 diabetes.

Comments

ZyVersa Therapeutics

Actualités

Dernières nouvelles pour ZyVersa Therapeutics (NASDAQ:ZVSA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL